CBInsights – Big Tech In Pharma

CBInsights' Big Tech in Pharma report looks at the acquisition and investment activity of big tech companies in the pharmaceutical industry. The report notes that big tech's acquisition activity dropped steeply in 2022, after a very active 2021. In terms of investments, the report states that Alphabet leads big tech in unique pharma investments (20) in 2022, followed by Microsoft (4) and GV (Google Ventures) is the most active big tech venture arm in pharma. The report also highlights that big tech companies are likely to double down on hardware and software, with the aim of capturing as much patient data as possible. Expect big tech companies to utilize their data expertise to discover and commercialize digital biomarkers. Additionally, big tech companies will continue to offer AI expertise to pharmaceutical companies and anticipate big tech to begin negotiating contracts with shared upside for drugs discovered as a result of their pharmaceutical partnerships.